ID: ALA174448

Max Phase: Preclinical

Molecular Formula: C29H40N6O4

Molecular Weight: 536.68

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1[nH]c([C@@H](Cc2cn(C)c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)NC2CCCCC2)nc1C(=O)O

Standard InChI:  InChI=1S/C29H40N6O4/c1-17(2)14-23(33-29(39)31-20-10-6-5-7-11-20)27(36)32-22(26-30-18(3)25(34-26)28(37)38)15-19-16-35(4)24-13-9-8-12-21(19)24/h8-9,12-13,16-17,20,22-23H,5-7,10-11,14-15H2,1-4H3,(H,30,34)(H,32,36)(H,37,38)(H2,31,33,39)/t22-,23+/m1/s1

Standard InChI Key:  QGQSORGTKDCUOS-PKTZIBPZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 536.68

Molecular Weight (Monoisotopic): 536.3111

AlogP: 4.35

#Rotatable Bonds: 10

Polar Surface Area: 141.14

Molecular Species: ACID

HBA: 5

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 1.24

CX Basic pKa: 5.77

CX LogP: 2.34

CX LogD: 0.93

Aromatic Rings: 3

Heavy Atoms: 39

QED Weighted: 0.26

Np Likeness Score: -0.76

References

1. von Geldern TW, Kester JA, Bal R, Wu-Wong JR, Chiou W, Dixon DB, Opgenorth TJ..  (1996)  Azole endothelin antagonists. 2. Structure-activity studies.,  39  (4): [PMID:8632420] [10.1021/jm950592+]

2. von Geldern TW, Hoffman DJ, Kester JA, Nellans HN, Dayton BD, Calzadilla SV, Marsh KC, Hernandez L, Chiou W, Dixon DB, Wu-Wong JR, Opgenorth TJ..  (1996)  Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.,  39  (4): [PMID:8632421] [10.1021/jm9505932]

Source

Source(1):

• Scientific Literature